RegeneRx President and CEO to Speak at Rodman & Renshaw Annual Global Investment Conference
08 September 2010 - 12:35AM
Business Wire
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (“the
Company” or “RegeneRx”) announced today that the Company will be
participating in the Rodman & Renshaw 12th Annual Global
Investment Conference being held at the Palace Hotel in New York
City from September 13th – 15th, 2010. J.J. Finkelstein, RegeneRx’s
president and chief executive officer, will deliver the Company’s
corporate presentation on Tuesday, September 14th, at 10:00 a.m.
(Eastern Time).
To listen and view the presentation investors may either visit
RegeneRx’s homepage at www.regenerx.com or click on the following
link: http://www.wsw.com/webcast/rrshq18/rgn. An archived copy of
the presentation will also be available on RegeneRx’s website.
Mr. Finkelstein will be available for one-on-one meetings with
investors participating in the Rodman & Renshaw Global
Investment Conference. For those who would like to schedule an
appointment with Regenerx management, please contact Kim Golodetz,
Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at
kgolodetz@lhai.com or contact your Rodman & Renshaw
representative.
About RegeneRx
Biopharmaceuticals, Inc.
RegeneRx is focused on the development of a novel therapeutic
peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection,
repair and regeneration. Currently RegeneRx has three products
in clinical development. RGN-352 is an injectable formulation to
treat cardiovascular and central nervous system diseases, as well
as other medical indications. RegeneRx has successfully completed a
Phase 1 clinical trial with RGN-352. RGN-259 is a sterile,
preservative-free topical eye drop for ophthalmic indications.
RegeneRx is currently supporting a physician-sponsored Phase 2 dry
eye study evaluating RGN-259. RGN-137, a topical gel formulation,
is currently being evaluated by RegeneRx in a Phase 2 clinical
trial for the treatment of epidermolysis bullosa. Other potential
uses for RGN-137 include the treatment of chronic dermal wounds and
reduction of scar tissue. Based on strong efficacy data in
pre-clinical studies, RegeneRx is initially targeting RGN-352 for
the treatment of patients who have suffered an acute myocardial
infarction, or heart attack. In addition to this indication, recent
pre-clinical efficacy data suggests that RGN-352 may also benefit
patients with multiple sclerosis and stroke. RegeneRx also has a
preclinical product candidate, RGN-457, which is an inhaled
formulation targeting cystic fibrosis and other pulmonary diseases.
In addition to the four pharmaceutical product candidates described
above, RegeneRx is pursuing the commercial development of peptide
fragments of Tβ4 for potential cosmeceutical use. RegeneRx holds 75
issued patents and has 261 patent applications pending worldwide
related to its products and holds an exclusive worldwide license
for Tβ4 from the National Institutes of Health.
Forward-Looking
Statements
Any statements in this press release that are not historical
facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve risks and uncertainties that
could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. You are urged to consider
statements that include the words “project,” “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,”
“would,” “could,” “will,” ”may,” “potential” or the negative of
those words or other similar expressions words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risks and uncertainties
inherent in our business, including, without limitation the risk
that our product candidates do not demonstrate safety and/or
efficacy in future clinical trials; risks related to our ability to
obtain financing to support our operations on commercially
reasonable terms; the progress, timing or success of our clinical
trials; difficulties or delays in development, testing, obtaining
regulatory approval for producing and marketing our product
candidates; regulatory developments; the size and growth potential
of the markets for our product candidates and our ability to serve
those markets; the scope and validity of patent protection for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and other risks described in the Company’s
filings with the Securities and Exchange Commission (“SEC”),
including those identified in the “Risk Factors” sections of the
annual report on Form 10-K for the year ended December 31, 2009,
filed with the SEC on March 31, 2010, and the quarterly report on
Form 10-Q for the quarter ended June 30, 2010, as well as other
filings it makes with the SEC. Any forward-looking statements in
this press release represent the Company’s views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. The Company anticipates that
subsequent events and developments may cause its views to change,
and the Company specifically disclaims any obligation to update
this information, as a result of future events or otherwise, except
as required by applicable law.
Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart
From May 2024 to Jun 2024
Regenerx Biopharm In (AMEX:RGN)
Historical Stock Chart
From Jun 2023 to Jun 2024